Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged ≥60 Years

2020109 citationsJournal Article

Authors

Kristi L. Williams · Janssen (Netherlands)

Arangassery Rosemary Bastian · Janssen (Netherlands)

Robert Feldman

Edmund Omoruyi · Janssen (Belgium)

Els De Paepe · Janssen (Belgium)

Jenny Hendriks · Janssen (Netherlands)

Hester van Zeeburg · Janssen (Netherlands)

Abstract

Ad26.RSV.preF (LD and HD) had an acceptable safety profile and elicited sustained humoral and cellular immune responses after a single immunization in older adults.

Topics & Keywords

Respiratory viral infections research Viral gastroenteritis research and epidemiology Virology and Viral Diseases

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: The Journal of Infectious Diseases

Volume 222, Issue 6, pp. 979-988

DOI: 10.1093/infdis/jiaa193

Field-Weighted Citation Impact: 11.00